pharmaphorum

MARCH 28, 2022

Dubai-based Altibbi already claims to be the largest operator in the Middle East region for Arabic language telehealth, and is poised to expand its services with the help of $44 million in new funding. Indian drugmaker Hikma Pharmaceuticals and Dubai’s Foundation Holdings led the round, which was also joined by Dubai-based Global Ventures and Amman-based DASH Ventures and will be used to expand Altibbi’s business into online pharmacy and diagnostics collection services.

52

52

Outsourcing Pharma

MARCH 28, 2022

The companies plan to work on developing personalized care solutions via digital pathology to come up with treatment options for patients with solid tumors.

52

52

pharmaphorum

MARCH 28, 2022

Roche has moved a step closer to extending the use of its B-cell lymphoma therapy Polivy into the first-line setting, after getting a recommendation for approval in the EU from EMA advisors. The CHMP backed Polivy (polatuzumab vedotin) for previously-untreated diffuse large B-cell lymphoma (DLBCL) in combination with R-CHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone) late last week.

Chemotherapy 52

Chemotherapy 52

Outsourcing Pharma

MARCH 28, 2022

The drug has received the agencyâs seal of approval to treat seizures associated with difficult-to-treat seizures associated with Lennox-Gastaut syndrome.

FDA 52

FDA 52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 28, 2022

GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity against new variants of the virus. The US regulator has trimmed back the emergency-use authorisation for Xevudy (sotrovimab), saying that new data suggests the current 500mg dose of the antibody is unlikely to be effective against the BA.2 subvariant of Omicron.

FDA 52

FDA Immunization Hospitals Vaccines 52

Outsourcing Pharma

MARCH 28, 2022

A new study will seek to understand the bodyâs response to the Nipah virus in order to support development of vaccines.

Vaccines 52

Vaccines 52

Pharma Times

MARCH 28, 2022

Digital health boost as new website focuses on dry eye disease, which currently affects one in four people across the UK

47

47

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . Noga Yerushalmi, investment director at M Ventures (the venture arm of Merck), tells us how AION Labs was formed and aspires to help ease the pharma industry’s shared challenges by offering its vast resources a new start-up.

Compounding 98

Compounding 98

Pharma Times

MARCH 28, 2022

Collaboration between Babylon Health and tech giant seeks to speed up historically slow patient access to data

Patient Care 47

Patient Care 47

Roots Analysis

MARCH 28, 2022

Over the last few decades, the pharmaceutical industry has been using batch processes for production of pharmaceutical products, which is a multi-phase process. However, the surge in the demand for drugs due to COVID-19 has led the pharmaceutical industry to shift on to a more agile and flexible technique- continuous, which is a single flow process allowing the industry to scale up quick, manufacture easily and shortens the drug supply chain.

Packaging 52

Packaging Dosage Vaccines 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA